NCT05645536
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Enrolling by Invitation
PHASE3Ages 18–51InterventionalTreatmentTolmar Inc.
~250 participants
Updated 2026-01-12 on ClinicalTrials.gov
What's tested:TOL2506TamoxifenLetrozole tabletsAnastrozole TabletsExemestane Tablets
At a glance
Recruiting sites
0 of 47 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The occurrences of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Measured over 4 years from enrolling in study
Conditions
Where it's being run
47 sites across 26 statesTexas6
Argentina5
Mexico4
Brazil3
Karnataka3
Maharashtra3
Kentucky2
Tennessee2
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Exclusion
Females:
What this trial measures
- The occurrences of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)4 years from enrolling in study